These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 9732339)

  • 1. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
    Gray A; Clarke P; Raikou M; Adler A; Stevens R; Neil A; Cull C; Stratton I; Holman R;
    Diabet Med; 2001 Jun; 18(6):438-44. PubMed ID: 11472461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):703-13. PubMed ID: 9732337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
    Matthews DR; Stratton IM; Aldington SJ; Holman RR; Kohner EM;
    Arch Ophthalmol; 2004 Nov; 122(11):1631-40. PubMed ID: 15534123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
    Clarke PM; Gray AM; Briggs A; Stevens RJ; Matthews DR; Holman RR;
    Diabetologia; 2005 May; 48(5):868-77. PubMed ID: 15834550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):713-20. PubMed ID: 9732338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
    Diabetologia; 1996 Dec; 39(12):1554-61. PubMed ID: 8960842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 24).
    Caro JJ; Lee K
    Curr Hypertens Rep; 2002 Dec; 4(6):417. PubMed ID: 12419165
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.
    Gray A; Raikou M; McGuire A; Fenn P; Stevens R; Cull C; Stratton I; Adler A; Holman R; Turner R
    BMJ; 2000 May; 320(7246):1373-8. PubMed ID: 10818026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Pharmacoeconomics; 2009; 27(3):221-30. PubMed ID: 19354342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade.
    Diabet Med; 1994 Oct; 11(8):773-82. PubMed ID: 7851072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.